Mary Haak-Frendscho - Health Technology Chair
Mary Haak-Frendscho is CEO and member of the Board of Directors of Blueline Bioscience, and a Venture Partner with Versant Ventures. Dr. Haak-Frendscho also serves on the Board of Directors at Northern Biologics and as Executive Chair of Sirenas.
Mary brings 25 years of biotechnology industry experience spanning global pharma to early stage biotech start-ups. Prior to joining Blueline, she established and was Chairman of the Board of Compugen, Inc. and was CEO and member of the Board at Igenica Biotherapeutics, Inc. Previously Mary was founding President, CSO and Board member of Takeda San Francisco, establishing and overseeing Takeda’s Center of Excellence for Biologics. Earlier in her career Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix (now Amgen), and Genentech, where she secured collaborative relationships with external corporate partners and led therapeutic programs. At Genentech, she played a key role in the development of omalizumab (Xolair®).